Pfizer's stock is cheap but faces operational challenges. Analyze its valuation and performance to make informed investment ...

PFIZER INC (PFE) is a large-cap growth stock in the Biotechnology & Drugs industry. The rating using this strategy is 90% based on the firm’s underlying fundamentals and the stock’s valuation.

Pfizer (PFE) has been one of the most searched-for stocks on Zacks.com lately. So, you might want to look at some of the facts that could shape the stock's performance in the near term. Shares of this ...

Our analysis is essentially based on how ... between trends in earnings estimate revisions and short-term stock price movements. Pfizer is expected to post earnings of $0.67 per share for the ...

Pfizer's attractive dividend yield and low P/E ratio make it appealing. Learn why PFE stock's valuation risks may be higher ...

The city’s pharma giants avoided much of the initial turbulence felt by the rest of the economy in the wake of President Donald Trump’s sweeping tariffs. The S&P 500 cratered Thursday following news ...

Investors in Pfizer Inc. (NYSE:PFE) need to pay close attention to the stock based on moves in the options market lately. That... One stock that might be an intriguing choice for investors right ...

Gold sell-off hitting interesting point Gold continues to suffer in the post-vaccine world. The Pfizer (NYSE:PFE) announcement... This article was written exclusively for Investing.com Or ...

The 12-month price targets assessed by analysts reveal further insights, featuring an average target of $152.57, a high ...

Lastly, Pfizer is a solid dividend stock. It now offers a beefy 6.8% yield, and has increased its payouts by 53.6% in the ...

Pfizer's top-selling product last year was Eliquis, which it co-markets with Bristol Myers Squibb. The blood thinner ...